Marketing pitches of ‘magic mushrooms’ and ‘psychedelics’ mask that psychotomimetics use exposes those vulnerable to serious adverse effects

Abstract

Get full access to this article

View all access options for this article.

References

Braillon

(2011) The many moral responsibilities of independent data-monitoring committees. Am J Bioeth 11: 16–17.

Council for International Organizations of Medical Sciences (1999) Guidelines for preparing core clinical-safety information on drugs second edition – Report of CIOMS working groups III and V. Geneva: Council for International Organizations of Medical Sciences.

Huxley

(1961) US State Department-sponsored speech to the Tavistock Group. California Medical School.

Morton

Sakai

Ashtari

, et al. (2023) Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption. J Psychopharmacol 37: 49–60.

Naudet

Fried

Cosgrove

, et al. (2022) Psychedelic drugs: More emphasis on safety issues. Nature 611: 449.

Tanne

(2004). Humphry Osmond. BMJ 328: 713.